Printer Friendly

STROKE VICTIMS TO GET AID SPECIAL IV DRUG MAY OFFSET USUAL DAMAGE.

Byline: Karen Maeshiro Staff Writer

LANCASTER - Local paramedics will administer a nerve cell-protecting agent to stroke victims before taking them to hospitals as part of a groundbreaking study.

Magnesium sulfate, a naturally occurring substance, dilates blood vessels in the brain and prevents calcium buildups in damaged nerve cells, possibly limiting the injury strokes can cause to victims' ability to talk, walk and perform other functions - if administered quickly.

``It's a generic, it's not patentable, so it's cheap,'' said Suzanne McCall, clinical site nurse coordinator for Antelope Valley Hospital and local fire stations. ``It's not a pharmaceutical study, so no big drug company is behind it. It's simply researchers working on something to help stroke patients. It's the first stroke study where we are treating patients in the field.''

Paramedics from Antelope Valley's Los Angeles County Fire Department Battalions 11 and 17 have been trained in recognizing stroke and in the study's procedures. They will administer the magnesium sulfate drug intravenously.

``We like doing new things,'' Fire Capt. Daniel Rodriguez said. ``We do like expanding our scope of practice because we are in business to save lives. The more we can do, the more 'toys' we have, the more tools in the box, the more benefits to the public we are saving.''

The Field Administration of Stroke Therapy - Magnesium Sulfate clinical research trial will involve nearly 70 hospitals in Los Angeles County under a $16 million grant from the National Institutes of Health. Antelope Valley Hospital was among the first to sign up and organizers are working to get Lancaster Community Hospital to take part.

Half the patients will receive the magnesium sulfate and half will receive a placebo.

Stroke is the third-leading cause of death and the primary cause of adult disability in the U.S. Each year, 750,000 Americans suffer a symptomatic stroke.

Clinical investigators, based at University of California, Los Angeles, want to see if magnesium sulfate can protect the threatened brain when administered to stroke victims by paramedics within the first two hours of the onset of stroke.

``This magnesium might be neuroprotective so it might help patients who are experiencing potential neurological injury due to the fact that the nerves, the neurons are not getting enough oxygen,'' said Dr. John Lynn, Antelope Valley Hospital's emergency department medical director and principal investigator for the study for the hospital. ``Magnesium might have a protective role to play in this process, to keep more of the neurological cells alive during a stroke.''

Participating will help improve AVH's relationship with Dr. Sidney Starkman, the study's co-principal investigator, and the stroke center he runs at UCLA, officials said.

``If we have complex stroke patients who come to the emergency room, we will have access to Dr. Starkman's expertise and stroke unit, which is one of the best in the world,'' Lynn said.

Karen Maeshiro, (661) 267-5744

karen.maeshiro(at)dailynews.com
COPYRIGHT 2005 Daily News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Daily News (Los Angeles, CA)
Date:Oct 9, 2005
Words:481
Previous Article:EASTSIDE MULLS TAXING DISTRICT.
Next Article:10,000 JOIN MAYOR FOR CLEANUP AROUND 16 OF CITY SCHOOLS.
Topics:


Related Articles
Spider toxins may take bite out of strokes.
Bold aim in stroke: spare the brain.
Stroke drug reveals a dark side.
Stroke rescue: can cells injected into the brain reverse paralysis?
PPA litigation on the rise after FDA warning.
BRAIN ATTACK.
Two drugs may enhance recovery from stroke.
Compound in bat saliva may aid stroke patients. (Nifty Spittle).
Protein may aid stroke recovery.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters